BRIEF-Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics

Like
1
Favorite

BRIEF-Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics

Reuters2022-02-02

Feb 2 (Reuters) - Entasis Therapeutics Holdings Inc

* INNOVIVA - ON FEB 1, 2022, SUBMITTED NON-BINDING PROPOSAL TO ACQUIRE ALL OF OUTSTANDING STOCK OF ENTASIS THERAPEUTICS HOLDINGS NOT OWNED BY INNOVIVA

* INNOVIVA SAYS SUBMITS PROPOSAL TO BUY ALL OF ENTASIS THERAPEUTICS' OUTSTANDING SHARES OF COMMON STOCK AT $1.80 PER SHARE FOR CASH

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

DonaldTing
·2022-02-02
I felt that there are more potential than 1.8 per share in the company.
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2208350190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-02 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2208350190","market":"us","top_or_hot":-1,"title":"BRIEF-Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics","media":"Reuters","content":"<html><body><p>Feb 2 (Reuters) - Entasis Therapeutics Holdings Inc</p><p> :</p><p>   * INNOVIVA - ON FEB 1, 2022, SUBMITTED NON-BINDING PROPOSAL TO ACQUIRE ALL OF OUTSTANDING STOCK OF ENTASIS THERAPEUTICS HOLDINGS NOT OWNED BY INNOVIVA</p><p>   * INNOVIVA SAYS SUBMITS PROPOSAL TO BUY ALL OF ENTASIS THERAPEUTICS' OUTSTANDING SHARES OF COMMON STOCK AT $1.80 PER SHARE FOR CASH</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-02 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 2 (Reuters) - Entasis Therapeutics Holdings Inc :   * INNOVIVA - ON FEB 1, 2022, SUBMITTED NON-BINDING PROPOSAL TO ACQUIRE ALL OF OUTSTANDING STOCK OF ENTASIS THERAPEUTICS HOLDINGS NOT OWNED BY ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2208350190","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2208350190","pubTimestamp":1643801141,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 2 (Reuters) - Entasis Therapeutics Holdings Inc :   * INNOVIVA - ON FEB 1, 2022, SUBMITTED NON-B","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INVA":"Innoviva, Inc.","ETTX":"Entasis Therapeutics Holdings Inc.","BK4007":"制药"},"translate_title":"简介-Innoviva提交非约束性收购Entasis疗法的提案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":1,"ETTX":0.9},"content_text":"Feb 2 (Reuters) - Entasis Therapeutics Holdings Inc :   * INNOVIVA - ON FEB 1, 2022, SUBMITTED NON-BINDING PROPOSAL TO ACQUIRE ALL OF OUTSTANDING STOCK OF ENTASIS THERAPEUTICS HOLDINGS NOT OWNED BY INNOVIVA   * INNOVIVA SAYS SUBMITS PROPOSAL TO BUY ALL OF ENTASIS THERAPEUTICS' OUTSTANDING SHARES OF COMMON STOCK AT $1.80 PER SHARE FOR CASHSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9091185223,"gmtCreate":1643805457481,"gmtModify":1676533858130,"author":{"id":"3572074767761780","authorId":"3572074767761780","name":"DonaldTing","avatar":"https://static.tigerbbs.com/4beaa97b2f4dc7dc0e3d9e4cd9f5f6b5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3572074767761780","authorIdStr":"3572074767761780"},"htmlText":"I felt that there are more potential than 1.8 per share&nbsp;in the company.&nbsp;","listText":"I felt that there are more potential than 1.8 per share&nbsp;in the company.&nbsp;","text":"I felt that there are more potential than 1.8 per share in the company.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091185223","repostId":2208350190,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}